Dexmedetomidine Dosage for Postoperative Delirium and Cognitive Function in Elderly TKA Patients
NCT ID: NCT06614881
Last Updated: 2024-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
132 participants
INTERVENTIONAL
2024-07-01
2024-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dexmetomedine for Post Operative Delirium in Elderly Patients Undergoing Elective Total Knee Replacement Under Spinal Anesthesia
NCT05707741
Intraoperative Infusion of Either Lidocaine or Dexmedetomidine on Regional Cerebral Oxygen Saturation and Postoperative Delirium in Elderly Patients Undergoing Abdominal Surgeries
NCT07108764
Intraoperative Infusion of Dexmedetomidine for Prevention of Postoperative Delirium in Elderly Patients
NCT05168280
Dexmedetomidine on Postoperative Cognitive Dysfunction and Serum Tau-217 Protein.
NCT06366412
Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting
NCT05640453
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
Normal saline
loading dose of saline was injected 10-min before induction of anesthesia.
Group D-1
Dexmedetomidine Injection [Precedex]
Dexmedetomidine (Precedex, 100 µg/ml) was provided as an intravenous (IV) loading dose of 1 µg/kg over 10-min
Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
Dexmedetomidine infusions were prepared to provide 0.5 µg/kg/h
Group D-2
Dexmedetomidine Injection [Precedex]
Dexmedetomidine (Precedex, 100 µg/ml) was provided as an intravenous (IV) loading dose of 1 µg/kg over 10-min
Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
Dexmedetomidine infusions were prepared to provide 0.7 µg/kg/h
Group D-3
Dexmedetomidine Injection [Precedex]
Dexmedetomidine (Precedex, 100 µg/ml) was provided as an intravenous (IV) loading dose of 1 µg/kg over 10-min
Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
Dexmedetomidine infusions were prepared to provide 1.1 µg/kg/h
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine Injection [Precedex]
Dexmedetomidine (Precedex, 100 µg/ml) was provided as an intravenous (IV) loading dose of 1 µg/kg over 10-min
Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
Dexmedetomidine infusions were prepared to provide 0.5 µg/kg/h
Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
Dexmedetomidine infusions were prepared to provide 0.7 µg/kg/h
Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
Dexmedetomidine infusions were prepared to provide 1.1 µg/kg/h
Normal saline
loading dose of saline was injected 10-min before induction of anesthesia.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients of American Society of Anesthesiologists Classification grades II-III;
Exclusion Criteria
* Patients show a high risk for getting Post Operative Delirium or have severe cognitive dysfunction;
* Patients had a history of uncompensated cardiac, renal, or hepatic diseases;
* Patients had uncontrolled diabetes mellitus or hypertension;
* Patients had other causes for limited movement;
* Patients had autoimmune disease, coagulopathy, severe anemia with a hemoglobin concentration of \<7 g%;
* Patients had local bone disorders that may prevent prosthesis stability;
* Patients had allergies or contraindications to the study drugs.
35 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed B. Abo elkheer
Lecturer of Anesthesiology, Pain, and ICU Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University
Tanta, El Gharbyia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
36264PR790/7/24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.